

**Tabelle A1-1: Anzahl der gemeldeten Patienten unter 15 Jahren aus der deutschen Wohnbevölkerung, Geschlechterverhältnis, Altersmedian, Anteil der Studienpatienten und Überlebenswahrscheinlichkeit nach ICCC-3-Diagnosegruppen (1996-2005)**  
**Number of cases under 15 years of age in Germany, sex ratio, age median, relative frequency of patients participating at clinical trials, and survival probabilities by ICCC-3-diagnostic groups (1996-2005)**

Diagnoses	Number of cases			Sex ratio		Age median (year month)	Trial par- ticipants (%)	Survival probabilities (%)	
	N	Relative (%)	Group (%)	boys to girls	5-year			5-year	10-year
<b>All malignancies</b>	<b>18327</b>	<b>100.0</b>	<b>100.0</b>	<b>1.2</b>	<b>5y 9 m</b>	<b>91.8</b>	<b>81</b>	<b>78</b>	
<b>Leukaemias, myeloproliferative and myelodysplastic diseases</b>	6221	33.9	100.0	1.2	5y 1 m	99.1	83	80	
Lymphoid leukaemias	4912	26.8	79.0	1.3	4y 10 m	99.7	88	85	
Acute myeloid leukaemias	891	4.9	14.3	1.1	6y 7 m	99.3	61	60	
Chronic myeloproliferative diseases	85	0.5	1.4	0.6	11y 2 m	91.8	63	60	
Myelodysplastic syndrome and other myeloproliferative diseases	279	1.5	4.5	1.4	5y 7 m	90.0	65	63	
Unspecified and other specified leukaemias	54	0.3	0.9	2.2	5y 8 m	100.0	55	55	
<b>Lymphomas and reticuloendothelial neoplasms</b>	<b>2170</b>	<b>11.8</b>	<b>100.0</b>	<b>1.9</b>	<b>10y 8 m</b>	<b>98.1</b>	<b>91</b>	<b>90</b>	
Hodgkin lymphomas	915	5.0	42.2	1.5	12y 6 m	98.5	96	95	
Non-Hodgkin lymphomas	1023	5.6	47.1	2.2	9y 2 m	97.8	87	86	
Burkitt lymphoma	214	1.2	9.9	4.2	8y 3 m	99.1	93	93	
Miscellaneous lymphoreticular neoplasms	13	0.1	0.6	0.9	0y 11 m	84.6	27	27	
Unspecified lymphomas	5	0.0	0.2	4.0	13y 3 m	100.0	100	100	
<b>CNS and miscellaneous intracranial and intraspinal neoplasms</b>	<b>4065</b>	<b>22.2</b>	<b>100.0</b>	<b>1.2</b>	<b>6y 11 m</b>	<b>80.4</b>	<b>71</b>	<b>65</b>	
Ependymomas and choroid plexus tumour	401	2.2	9.9	1.3	3y 10 m	78.1	71	57	
Astrocytomas	1857	10.1	45.7	1.1	7y 3 m	82.3	77	73	
Intracranial and intraspinal embryonal tumours	945	5.2	23.2	1.7	6y 3 m	84.1	61	52	
Other gliomas	292	1.6	7.2	1.1	7y 8 m	83.2	39	36	
Other specified intracranial and intraspinal neoplasms	500	2.7	12.3	1.1	8y 11 m	70.0	93	90	
Unspecified intracranial and intraspinal neoplasms	70	0.4	1.7	1.4	6y 0 m	54.3	63	61	
<b>Neuroblastoma and other peripheral nervous cell tumours</b>	<b>1479</b>	<b>8.1</b>	<b>100.0</b>	<b>1.2</b>	<b>1y 3 m</b>	<b>98.8</b>	<b>78</b>	<b>75</b>	
Neuroblastoma and ganglioneuroblastoma	1473	8.0	99.6	1.2	1y 3 m	99.1	78	75	
Other peripheral nervous cell tumours	6	0.0	0.4	1.0	9y 6 m	16.7	69	69	
<b>Retinoblastoma</b>	<b>359</b>	<b>2.0</b>	<b>100.0</b>	<b>1.1</b>	<b>1y 1 m</b>	-	<b>91</b>	<b>89</b>	
<b>Renal tumours</b>	<b>1033</b>	<b>5.6</b>	<b>100.0</b>	<b>0.9</b>	<b>3y 3 m</b>	<b>95.5</b>	<b>90</b>	<b>90</b>	
Nephroblastoma and other non-epithelial renal tumours	1015	5.5	98.3	0.9	3y 2 m	96.0	91	90	
Renal carcinomas	18	0.1	1.7	0.6	10y 9 m	66.7	83	83	
Unspecified malignant renal tumours	0	0.0	0.0	-	-y - m	-	-	-	
<b>Hepatic tumours</b>	<b>185</b>	<b>1.0</b>	<b>100.0</b>	<b>2.1</b>	<b>1y 10 m</b>	<b>97.3</b>	<b>63</b>	<b>59</b>	

Tabelle A1-1 Forts.

Table A1-1 cont.

Diagnoses	Number of cases			Sex ratio boys to girls	Age median (year month)	Trial par- ticipants (%)	Survival probabilities (%)	
	N	Relative (%)	Group (%)				5-year	10-year
Hepatoblastoma	147	0.8	79.5	2.1	1y 4m	98.6	67	67
Hepatic carcinomas	37	0.2	20.0	2.7	9y 8m	91.9	47	30
Unspecified malignant hepatic tumours	1	0.0	0.5	-	14y 5m	100.0	100	100
<b>Malignant bone tumours</b>	<b>807</b>	<b>4.4</b>	<b>100.0</b>	<b>1.1</b>	<b>11y 6m</b>	<b>98.4</b>	<b>70</b>	<b>66</b>
Osteosarcomas	412	2.2	51.1	1.0	11y 11m	98.5	71	67
Chondrosarcomas	11	0.1	1.4	0.8	14y 0m	63.6	67	67
Ewing tumour and related sarcomas of bone	375	2.0	46.5	1.4	10y 11m	99.5	70	66
Other specified malignant bone tumours	8	0.0	1.0	0.3	10y 11m	87.5	67	67
Unspecified malignant bone tumours	1	0.0	0.1	-	13y 10m	100.0	100	100
<b>Soft tissue and other extraosseous sarcomas</b>	<b>1129</b>	<b>6.2</b>	<b>100.0</b>	<b>1.2</b>	<b>6y 3m</b>	<b>95.7</b>	<b>75</b>	<b>70</b>
Rhabdomyosarcomas	653	3.6	57.8	1.3	4y 8m	98.6	74	70
Fibrosarcomas, peripheral nerve sheath tumours and other fibromatous neoplasms	93	0.5	8.2	0.9	8y 11m	83.9	73	64
Kaposi sarcoma	0	0.0	0.0	-	-y -m	-	-	-
Other specified soft tissue sarcomas	307	1.7	27.2	1.1	10y 1m	94.1	78	71
Unspecified soft tissue sarcomas	76	0.4	6.7	0.9	8y 2m	92.1	69	65
<b>Germ cell tumours, trophoblastic tumours and neoplasms of gonads</b>	<b>601</b>	<b>3.3</b>	<b>100.0</b>	<b>0.8</b>	<b>7y 11m</b>	<b>96.7</b>	<b>94</b>	<b>92</b>
Intracranial and intraspinal germ cell tumours	164	0.9	27.3	2.0	11y 1m	92.7	88	86
Malignant extracranial and extragonadal germ cell tumours	175	1.0	29.1	0.5	0y 6m	97.7	95	92
Malignant gonadal germ cell tumours	252	1.4	41.9	0.6	9y 10m	99.6	97	96
Gonadal carcinomas	8	0.0	1.3	-	11y 9m	62.5	60	60
Other and unspecified malignant gonadal tumours	2	0.0	0.3	-	2y 8m	100.0	100	100
<b>Other malignant epithelial neoplasms and malignant melanomas</b>	<b>259</b>	<b>1.4</b>	<b>100.0</b>	<b>0.7</b>	<b>11y 9m</b>	<b>63.3</b>	<b>77</b>	<b>71</b>
Adrenocortical carcinomas	28	0.2	10.8	0.6	3y 4m	85.7	43	43
Thyroid carcinomas	130	0.7	50.2	0.5	12y 5m	79.2	96	89
Nasopharyngeal carcinomas	23	0.1	8.9	2.3	13y 2m	100.0	90	81
Malignant melanomas	18	0.1	6.9	0.8	7y 9m	-	47	47
Skin carcinomas	7	0.0	2.7	0.8	10y 6m	-	64	64
Other and unspecified carcinomas	53	0.3	20.5	1.0	12y 2m	26.4	57	44
<b>Others and unspecified malignant neoplasms</b>	<b>19</b>	<b>0.1</b>	<b>100.0</b>	<b>1.4</b>	<b>5y 9m</b>	<b>68.4</b>	<b>63</b>	<b>63</b>
Other specified malignant tumours	15	0.1	78.9	1.5	5y 9m	66.7	68	68
Other unspecified malignant tumours	4	0.0	21.1	1.0	8y 4m	75.0	33	33

- insufficient data